Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab

Naoki Haratake, Gouji Toyokawa, Tetsuzo Tagawa, Yuka Kozuma, Taichi Matsubara, Shinkichi Takamori, Takaki Akamine, Yuichi Yamada, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

10 引用 (Scopus)

抄録

Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. Patients and Methods: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. Conclusion: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.

元の言語英語
ページ(範囲)5713-5717
ページ数5
ジャーナルAnticancer research
37
発行部数10
DOI
出版物ステータス出版済み - 10 1 2017

Fingerprint

Ligands
Drug Therapy
Biopsy
Therapeutics
nivolumab
Non-Small Cell Lung Carcinoma
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Haratake, N., Toyokawa, G., Tagawa, T., Kozuma, Y., Matsubara, T., Takamori, S., ... Maehara, Y. (2017). Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. Anticancer research, 37(10), 5713-5717. https://doi.org/10.21873/anticanres.12009

Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. / Haratake, Naoki; Toyokawa, Gouji; Tagawa, Tetsuzo; Kozuma, Yuka; Matsubara, Taichi; Takamori, Shinkichi; Akamine, Takaki; Yamada, Yuichi; Oda, Yoshinao; Maehara, Yoshihiko.

:: Anticancer research, 巻 37, 番号 10, 01.10.2017, p. 5713-5717.

研究成果: ジャーナルへの寄稿記事

Haratake, N, Toyokawa, G, Tagawa, T, Kozuma, Y, Matsubara, T, Takamori, S, Akamine, T, Yamada, Y, Oda, Y & Maehara, Y 2017, 'Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab', Anticancer research, 巻. 37, 番号 10, pp. 5713-5717. https://doi.org/10.21873/anticanres.12009
Haratake, Naoki ; Toyokawa, Gouji ; Tagawa, Tetsuzo ; Kozuma, Yuka ; Matsubara, Taichi ; Takamori, Shinkichi ; Akamine, Takaki ; Yamada, Yuichi ; Oda, Yoshinao ; Maehara, Yoshihiko. / Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab. :: Anticancer research. 2017 ; 巻 37, 番号 10. pp. 5713-5717.
@article{58e5754eddc44461b238cf0177b3731a,
title = "Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab",
abstract = "Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. Patients and Methods: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. Conclusion: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.",
author = "Naoki Haratake and Gouji Toyokawa and Tetsuzo Tagawa and Yuka Kozuma and Taichi Matsubara and Shinkichi Takamori and Takaki Akamine and Yuichi Yamada and Yoshinao Oda and Yoshihiko Maehara",
year = "2017",
month = "10",
day = "1",
doi = "10.21873/anticanres.12009",
language = "English",
volume = "37",
pages = "5713--5717",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Positive conversion of PD-L1 expression after treatments with chemotherapy and nivolumab

AU - Haratake, Naoki

AU - Toyokawa, Gouji

AU - Tagawa, Tetsuzo

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Takamori, Shinkichi

AU - Akamine, Takaki

AU - Yamada, Yuichi

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. Patients and Methods: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. Conclusion: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.

AB - Background/Aim: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course. Patients and Methods: We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis. Results: Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment. Conclusion: These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.

UR - http://www.scopus.com/inward/record.url?scp=85031113268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031113268&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12009

DO - 10.21873/anticanres.12009

M3 - Article

VL - 37

SP - 5713

EP - 5717

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -